Frontlight ResearchEarly access
WithdrawnNo phase
Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Coronary Heart Disease
Key facts
- Who runs it
- Henan Institute of Cardiovascular Epidemiology
- Trial code
- Status
- Withdrawn
- Started
- 30 Dec 2024
- Expected to end
- 30 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Indobufen
- Aspirin
- Record updated
- 20 November 2024
- Why it stopped
- shortage of funds
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- 18 years < age ≤ 85 years
- Patients with confirmed stable coronary heart disease (must meet at least one of the following conditions); 2.1 a stenosis confirmed by Coronary angiography or dual-source CT, but the stenosis of the Left Main Artery (LMA) diameter is less than 50%, the stenosis of the left anterior descending branch(LAD)is less than 70%, and the stenosis of the two or three coronary arteries diameter is less than 70%, patient has no corresponding evidence of ischemia; 2.2 Patients after percutaneous coronary intervention (PCI): Dual antiplatelet therapy (DAPT) time is greater than 9 months, without cardiovascular events and ischemic symptoms; and currently receiving aspirin 100 mg/d with clopidogrel 75 mg/d or ticagrelor 90mg (bid) dual antiplatelet therapy; 2.3 Patients after coronary artery bypass graft (CABG): Dual antiplatelet therapy (DAPT) time is greater than 9 months, without cardiovascular events and ischemic symptoms; and currently receiving aspirin 100 mg/d with clopidogrel 75 mg/d or ticagrelor 90mg (bid) dual antiplatelet therapy
- Willing to sign the informed consent
Who cannot take part
- Acute coronary syndrome (ACS) occurred within 3 months before screening
- Percutaneous coronary intervention or CABG surgery within 9 months before screening
- Use of non-steroidal anti-inflammatory drugs (within 3 months)
- Any other conditions (such as atrial fibrillation, pulmonary embolism, lower extremity venous thrombosis, artificial heart valve, etc.) who need oral or intravenous anticoagulation treatment
- A positive history of Chronic Obstructive Pulmonary Disease (COPD)
- bleeding tendency or severe lung disease
- Active pathological bleeding
- History of intracranial hemorrhage (less than 3 months)
- Allergic to indobufen / aspirin (or any of its ingredients)
- Have a history of drug or alcohol abuse in the past 2 years
- In the past 3 months, the Arachidonic acid-induced platelet aggregation rate≥ 50%; inhibition rate ≤ 20% in the aspirin combined with clopidogrel treated patients
- Congestive heart failure or left ventricular ejection fraction <35%
- Severe liver injury (transaminases exceeding the upper limit of 2 times and above)
- Hematological diseases, platelet count <100000 / mm3 or hemoglobin <10g / dL
- Creatinine clearance <30ml/min
- Pregnancy, lactation and those who have a birth plan
About the trial
What the trial wants to find out
This study evaluates the effect of Indobufen and Aspirin on platelet aggregation and long term prognosis in patients with stable coronary heart disease.
The 2 groups in the trial
- IndobufenTreatment being tested
200 mg Indobufen, bid po, 90 days
- AspirinExisting treatment, for comparison
100 mg Aspirin, qd po, 90 days
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Stable Coronary Heart Disease. A Prospective, Randomized and Controlled,Single Blind, Single-center, Opening Study
- Record updated
- 20 November 2024